Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Moderate-To-Severe Atopic Dermatitis

Loading news article.

Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Moderate-To-Severe Atopic Dermatitis | WAPE

Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Moderate-To-Severe Atopic Dermatitis

Article summary

Related companies

Comments —